Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab-Reference-Cited by-同舟云学术

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Published:2022-01-14 Issue:3 Volume:45 Page:167-179
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Lambert Stacie L.,Zhang Chun,Guo Claire,Turan Tolga,Masica David L.,Englert Stefan,Fang Yuni,Sheridan James,McLaughlin Robert Tyler,Tribouley Catherine,Vosganian Greg,Afar Daniel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference46 articles.

1. Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis;Weng;Onco Targets Ther,2018

2. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable;Prasad;Semin Oncol,2017

3. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer;Ancevski Hunter;Mol Diagn Ther,2018

4. Beyond PD-L1 testing—emerging biomarkers for immunotherapy in non-small cell lung cancer;Voong;Ann Transl Med,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications;Biomarker Research;2024-09-02

2. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

3. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;Nature Communications;2024-03-27

4. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade;Journal of Experimental & Clinical Cancer Research;2024-03-16

5. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;2023-12-04